ArticleBMC psychiatry2018
The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study.
Article in BMC psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Prevalence and predictors of metabolic syndrome among psychiatric patients receiving antipsychotic treatment in Africa: a systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Qatar's Silent Epidemic: A Comprehensive Meta-analysis on the Prevalence of Metabolic Syndrome.Current diabetes reviews · 2025Pooled it
- Peripheral blood RNA-seq analysis in bipolar and schizophrenia spectrum disorders: modest influence of antipsychotic treatment.Frontiers in pharmacology · 2026Article
- Prevalence and associated factors of metabolic syndrome among Omani adults with mental illnesses: a cross-sectional study.Scientific reports · 2025Article
- Mortality in Qatari individuals with mental illness: a retrospective cohort study.Annals of general psychiatry · 2024Article
- Variational autoencoders learn transferrable representations of metabolomics data.Communications biology · 2022Article
- Proteomic Analysis of Plasma Markers in Patients Maintained on Antipsychotics: Comparison to Patients Off Antipsychotics and Normal Controls.Frontiers in psychiatry · 2022Article
- Metabolic syndrome and associated factors among severely ill psychiatric and non-psychiatric patients: a comparative cross-sectional study in Eastern Ethiopia.Diabetology & metabolic syndrome · 2021Article
- Quality of diabetes care in patients with schizophrenia: a case-control study in Qatar.BMC psychiatry · 2021Article
- Cardiovascular risk assessment for patients with serious mental illnesses: An internal review.Qatar medical journal · 2021Article
- A strategy to incorporate prior knowledge into correlation network cutoff selection.Nature communications · 2020Article
- Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study.Community mental health journal · 2020Article
- Prevalence of metabolic syndrome in the Gulf Cooperation Council countries: meta-analysis of cross-sectional studies.Journal of exercise rehabilitation · 2020Review
- Metabolic syndrome among adults in Qatar: A review of the literature across medical specialties.Qatar medical journal · 2020Article
- Relationships between sleep patterns and metabolic profile in patients maintained on antipsychotics: a cross-sectional comparative study.Neuropsychiatric disease and treatment · 2019Article
- Association between obesity/overweight and dental caries in psychiatric patients.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundMetabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS.
methodsA cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group.
resultsThe two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group.
conclusionsThe prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.